Assignee
VERASTEM INC
US·9 granted patents·22 pending applications·21 citations·filing 2012–2023
Top patents by PatentIndex Score
31 records- 0191US10532056B2Therapeutic compositions, combinations, and methods of useVERASTEM INC·Filed 2016·Granted Jan 14, 2020·6 cites·27 claims
- 0289US11873296B2Solid forms of a dual RAF/MEK inhibitorVERASTEM INC·Filed 2022·Granted Jan 16, 2024·2 cites·27 claims
- 0385US10406158B2Methods and compositions for treating abnormal cell growthVERASTEM INC·Filed 2018·Granted Sep 10, 2019·5 cites·11 claims
- 0485US9962385B2Methods and compositions for treating abnormal cell growthVERASTEM INC·Filed 2015·Granted May 8, 2018·6 cites·16 claims
- 0582US11564927B2Therapeutic compositions, combinations, and methods of useVERASTEM INC·Filed 2019·Granted Jan 31, 2023·1 cites·18 claims
- 0675US2023321097A1Methods and compositions for treating abnormal cell growthVERASTEM INC·Filed 2022·Application pending·0 cites
- 0773US2024000790A1Therapeutic compositions, combinations, and methods of useVERASTEM INC·Filed 2022·Application pending·0 cites
- 0872US12509450B2Solid forms of a dual RAF/MEK inhibitorVERASTEM INC·Filed 2023·Granted Dec 30, 2025·0 cites·20 claims
- 0968US2023104303A1Compositions and methods for treatment of abnormal cell growthVERASTEM INC·Filed 2022·Application pending·0 cites
- 1067US2015080368A1Sulfonyl amide derivatives for the treatment of abnormal cell growthVERASTEM INC·Filed 2014·Application pending·0 cites
- 1165US2025367201A1Combination therapy for treating abnormal cell growthVERASTEM INC·Filed 2023·Application pending·0 cites
- 1263US9505719B2Synthesis and use of kinase inhibitorsVERASTEM INC·Filed 2013·Granted Nov 29, 2016·1 cites·31 claims
- 1362US9138437B2Pyrimidine substituted purine compounds as kinase (S) inhibitorsVERASTEM INC·Filed 2014·Granted Sep 22, 2015·0 cites·6 claims
- 1461US2024382485A1Methods of treating abnormal cell growthVERASTEM INC·Filed 2022·Application pending·0 cites
- 1560US2025049792A1Combination therapy for treating abnormal cell growthVERASTEM INC·Filed 2022·Application pending·0 cites
- 1659US2020147080A1Methods and compositions for treating abnormal cell growthVERASTEM INC·Filed 2019·Application pending·0 cites
- 1758US2025064804A1Combination therapy for treating abnormal cell growthVERASTEM INC·Filed 2022·Application pending·0 cites
- 1857US2023330088A1Combination therapy for treating abnormal cell growthVERASTEM INC·Filed 2021·Application pending·0 cites
- 1955US2023103007A1Combination therapy for treating abnormal cell growthVERASTEM INC·Filed 2021·Application pending·0 cites
- 2055US2025099467A1Combination therapy for treating abnormal cell growthVERASTEM INC·Filed 2023·Application pending·0 cites
- 2154US2014066620A1Pyrimidine substituted purine derivativesVERASTEM INC·Filed 2013·Application pending·0 cites
- 2254US2025009746A1Combination therapy for treating abnormal cell growthVERASTEM INC·Filed 2022·Application pending·0 cites
- 2352US2020038331A1Compositions and methods for treatment of abnormal cell growthVERASTEM INC·Filed 2019·Application pending·0 cites
- 2451US2024115571A1Combination therapy for treating abnormal cell growthVERASTEM INC·Filed 2022·Application pending·0 cites
- 2550US2016207927A1Pyrimidine substituted purine compounds as kinase (s) inhibitorsVERASTEM INC·Filed 2015·Application pending·0 cites
- 2646US2023201198A1Methods of treating abnormal cell growthVERASTEM INC·Filed 2021·Application pending·0 cites
- 2742US9375402B2Oral formulations of kinase inhibitorsVERASTEM INC·Filed 2013·Granted Jun 28, 2016·0 cites·4 claims
- 2841US2015190346A1Compositions and methods for treatment of abnormal cell growthVERASTEM INC·Filed 2015·Application pending·0 cites
- 2940US2015071947A1Methods of identifying gene isoforms for anti-cancer treatmentsVERASTEM INC·Filed 2013·Application pending·0 cites
- 3040US2014336248A1Therapeutic compositions and related methods of useVERASTEM INC·Filed 2012·Application pending·0 cites
- 3140US2015030615A1Biomarkers for cancer stem cells and related methods of useVERASTEM INC·Filed 2013·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →